Mandate

Vinge represents Symrise in connection with its mandatory offer on Probi

February 06, 2014

Symrise AG has, after having acquired shares corresponding to approximately 30.03 per cent of the votes in Probi AB (publ), launched a mandatory offer to the shareholders in Probi, with an offered price of SEK 40.10 per share. Vinge represents Symrise in connection with the mandatory offer.

Symrise is a global supplier of fragrances, flavourings, cosmetic, active ingredients, and raw materials as well as functional ingredients. The company’s share is listed on the Frankfurt Stock Exchange and the market capitalisation of Symrise is EUR 4 billion.

Probi is a research-driven biotechnology company focused on the global probiotics market. Through Probi’s research Probi has developed probiotics with well-documented beneficial health effects. The company’s share is listed on NASDAQ OMX Stockholm, Small cap and the market capitalisation of Probi is approximately MSEK 375.

Vinge’s team primarily consists of Jesper Schönbeck, Oskar Belani, Joakim Hagberg and Sabina Börjesson.

Related

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026

Vinge advises HealthCap in conjunction with its investment in AMRA Medical

HealthCap is investing in AMRA Medical AB, a company that analyses whole-body MRI images to classify and quantify an individual’s muscle and fat tissue throughout the body and places this in relation to human health and disease.
September 15, 2026

Vinge has advised EQT managed Scaleup Europe Fund on its investment in Tandem Health

Vinge has advised EQT managed Scaleup Europe Fund as lead investor in Tandem Health's USD 100 million Series B investment round, with participation from existing investors Kinnevik, Northzone, Amino Collective and Visionaries. Tandem Health is an AI healthcare company founded in 2023 and headquartered in Sweden. Tandem Health operates as an AI partner within the healthcare sector across Europe, providing AI medical assistant support to clinicians in connection with patient visits.
September 15, 2026